GlassScriptPhysician profile
Scott Ira Kahan
NPI 1699921890
$264,949.33
in general payments reported to CMS, 2019-2025
10 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
See the full distribution for Public Health & General Preventive Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $39K · 2021: $24K · 2022: $31K · 2023: $20K · 2024: $25K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Consulting Fee: $63K · Travel and Lodging: $5,984 · Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,287.50 |
| Consulting Fee | $63,282.20 |
| Travel and Lodging | $5,984.43 |
| Food and Beverage | $1,177.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $84,378.10 | 2025 | Zepbound, Mounjaro |
| Vivus LLC | $49,148.71 | 2020-2022 | |
| Eli Lilly and Company | $36,245.42 | 2021-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,777.51 | 2024-2025 | |
| Novo Nordisk INC | $27,254.63 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $27,194.36 | 2021-2025 | Contrave |
| Novo Nordisk As | $5,503.92 | 2019 | |
| Pfizer INC. | $5,320.00 | 2020 | |
| Covidien LP | $106.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.